Home/Filings/4/0001437749-22-013130
4//SEC Filing

Dalvey David 4

Accession 0001437749-22-013130

CIK 0001603454other

Filed

May 18, 8:00 PM ET

Accepted

May 19, 8:41 PM ET

Size

24.6 KB

Accession

0001437749-22-013130

Insider Transaction Report

Form 4
Period: 2022-05-17
Dalvey David
Director
Transactions
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-05-178,2000 total
    Exercise: $16.23Exp: 2027-10-19Common Stock (8,200 underlying)
  • Award

    Stock Option (right to buy)

    2022-05-17+8,2008,200 total
    Exercise: $5.50Exp: 2027-10-19Common Stock (8,200 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-05-173,2010 total
    Exercise: $19.45Exp: 2028-05-14Common Stock
  • Award

    Stock Option (right to buy)

    2022-05-17+3,2013,201 total
    Exercise: $5.50Exp: 2028-05-14Common Stock (3,201 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-05-175,0540 total
    Exercise: $22.45Exp: 2029-05-16Common Stock (5,054 underlying)
  • Award

    Stock Option (right to buy)

    2022-05-17+5,0545,054 total
    Exercise: $5.50Exp: 2029-05-16Common Stock (5,054 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-05-172,3100 total
    Exercise: $26.99Exp: 2031-05-12Common Stock (2,310 underlying)
  • Award

    Stock Option (right to buy)

    2022-05-17+2,3102,310 total
    Exercise: $5.50Exp: 2031-05-12Common Stock (2,310 underlying)
  • Award

    Stock Option (right to buy)

    2022-05-17+24,44924,449 total
    Exercise: $5.50Exp: 2032-05-17Common Stock (24,449 underlying)
Holdings
  • Common Stock

    (indirect: By Brightstone Venture Capital Fund, LP)
    250,000
  • Common Stock

    9,325
  • Stock Option (right to buy)

    Exercise: $5.10Exp: 2030-05-14Common Stock (12,654 underlying)
    12,654
Footnotes (4)
  • [F1]The Reporting Person is the General Partner of Brightstone Venture Capital Fund, LP.
  • [F2]100% vested.
  • [F3]The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on May 17, 2022 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of the Stock Option has been amended to reduce such exercise price to $5.50 per share, the closing price of the issuer's common stock on The Nasdaq Capital Market as of the date of such repricing. There have been no other changes to the terms of the Stock Option.
  • [F4]This Option will vest and become exercisable on April 30, 2023, or if earlier, the date of the Company's 2023 Annual Meeting of Stockholders.

Issuer

Celcuity Inc.

CIK 0001603454

Entity typeother

Related Parties

1
  • filerCIK 0001296457

Filing Metadata

Form type
4
Filed
May 18, 8:00 PM ET
Accepted
May 19, 8:41 PM ET
Size
24.6 KB